Prolgolimab

Unassigned

New Medicines

Metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR mutation or ALK translocation - in combination with pemetrexed and cisplatin (or carboplatin)

Information

New molecular entity
Biocad
Biocad

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Anti-programmed cell death-1 (PD-1) monoclonal antibody
In 2016, around 33,000 people were diagnosed with NSCLC in England. Around 53% had stage IV disease, and approximately 70% of NSCLC have non-squamous histology, either large-cell undifferentiated carcinoma or adenocarcinoma [1].
Metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR mutation or ALK translocation - in combination with pemetrexed and cisplatin (or carboplatin)
Intravenous infusion